



### RESEARCH ARTICLE

## “ANALYSIS OF EFFICACY OF FRESH FROZEN PLASMA TRANSFUSION IN ORGANOPHOSPHORUS POISONING IN INTUBATED PATIENTS -A RANDOMIZED CONTROL STUDY”

Dr. Surendra E.M<sup>1</sup>, Dr. Kallesh Shamanur<sup>2</sup>, Dr. Manjunatha B.H<sup>3</sup>, Dr. Pritish Sharma<sup>4</sup> and Dr. Gagan A. Pai<sup>5</sup>

1. Professor, Department of Emergency Medicine, JJM Medical College.
2. Associate Professor, Department of Emergency Medicine, JJM Medical College.
3. Associate Professor, Department of Emergency Medicine, JJM Medical College.
4. Post Graduate, Department of Emergency Medicine, JJM Medical College.
5. Post Graduate, Department of Emergency Medicine, JJM Medical College.

### Manuscript Info

### Abstract

#### Manuscript History

Received: 25 July 2024

Final Accepted: 27 August 2024

Published: September 2024

Copyright, IJAR, 2024,. All rights reserved.

### Aims & Objectives:-

To determine the reduction of length of ICU stay and mortality in organophosphorus poisoning patients of intubated patients using Fresh frozen plasma as add on therapy.

### Materials & Methods:-

#### Study design:

A case control study was conducted on ventilated organophosphorus patients admitted to Emergency Medicine of Bapuji Hospital.

#### Study period:

April 2024 to September 2024 (6 months)

#### Sample size:

sample size comes to be minimum of 22 in each group

#### Data analysis:

SPSS vers. 24.0 was used to do the analysis.

#### Exclusion Criteria:

1. Age < 18
2. Poisoning cases other than organophosphorus compounds.
3. Patients having serum cholinesterase level more than 2000 IU/L
4. Patients with comorbidities including diabetes, hypertension, malignancy etc

**Corresponding Author:- Dr Pritish Sharma**

Address:- Department of Emergency Medicine, JJM Medical College.

Patients were divided into two groups of 22 each. The control group received atropine and oximes only and the study group received atropine and oximes along with FFP 2 units (400 ml) on daily basis until patient is extubated or pseudocholinesterase level above 2000 IU.

### Results:-

Our study did show significant mortality benefit in FFP transfused patients (9.1% compared to control 31.8%). The mean number of days of hospital stay was 4.1 in cases with SD of 1.62 whereas it was 5.8 in control with SD of 2.00 and this was statistically significant  $p=0.004$ .

### Conclusion:-

The use of FFP was found to have mortality benefit and also reduces length of hospital stay in our study. Larger trials are required to determine the dosage and duration of FFP transfusion in order to add it to the standard therapy.

### Introduction:-

Organophosphates are widely used as insecticides in agricultural practice. Due to its easy availability there is significant increase in the household incidence of occupational, accidental or homicidal consumptions.<sup>1</sup>

Organophosphorus compound poisoning is among one of the most common medical acute emergencies associated with high mortality rate. Organophosphates after entering into circulation binds to acetylcholinesterase & inhibit the enzyme, resulting in increased unbound acetylcholine. This manifests as cholinergic crisis, having both nicotinic and muscarinic actions. Muscle weakness and bronchorrhea lead to respiratory failure which is the leading cause of death in organophosphate poisoning.

Serum pseudocholinesterase levels to be checked for patient with organophosphorus poisoning. Patient presenting to the Emergency department with organophosphorus poisoning, airway, breathing, circulation should be managed first following which decontamination is done. Patient is then administered atropine which is a muscarinic and nicotinic antagonist; and pralidoxime which is acetylcholinesterase reactivator. Atropine is preferred over scopolamine and glycopyrrolate as it has both central and peripheral antimuscarinic effects. Pralidoxime effectively reactivates red cell acetylcholinesterase inhibited by diethyl OP inhibited enzyme such as chlorpyrifos, quinalphos but only moderately reactivates dimethyl OP-inhibited enzyme such as dimethoate, fenthions.

FFP is now suggested as a useful therapy for Organophosphorus poisoning as it contains cholinesterase enzyme. The serum cholinesterase enzyme in FFP will confiscate free organophosphorus compound which is present in blood, thus preventing toxic effect on neuromuscular junction.

This study is done to analyse the effectiveness of FFP in ventilated patients of organophosphorus poisoning to compare mortality in atropine+ oxime group and atropine+ oxime+ FFP group. No study has been done to fill this gap hence the need for this study.

### AIMS & OBJECTIVES:

To determine the reduction of length of ICU stay and mortality in organophosphorus poisoning patients of intubated patients using Fresh frozen plasma as add on therapy.

### MATERIALS & METHODS:

- **Study design:** case control study
- **Study period:** April 2024 to September 2024 (6 months)
- **Sample size:** The study was conducted on all confirmed cases of organophosphorus pesticide poisoned patients admitted to Bapuji Hospital, Davangere during the study period of 6 months.

$$n = \frac{2 (Z\alpha + Z\beta)^2 * S^2}{d^2}$$

- Where
- $Z\alpha = 1.96$  at 95% confidence level And  $Z\beta = 1.28$  at 90% power
- $S$  = combined standard deviation and
- $d$  = Mean difference
- With 95% confidence level and 80% power with respect to (Dayananda VP et al<sup>1</sup>) sample size comes to be minimum of 22 in each group

**Data analysis:** Analysis will be done by descriptive statistics. Comparison between the groups was done by students unpaired t test or Mann Whitney U test as per the normality of the data. Chisquare test was used for qualitative data. A statistical package SPSS vers. 24.0 will be used to do the analysis.  $p < 0.05$  will be considered as significant

**Inclusion criteria:**

- All the OP poisoning intubated cases confirmed by history, circumstantial evidence of consumption, characteristic clinical examination and basic laboratory investigations.

**Exclusion criteria:**

- Age < 18
- Poisoning cases other than organophosphorus compounds.
- Patients having serum cholinesterase level more than 2000 IU/L
- Patients with comorbidities including diabetes, hypertension, malignancy etc

**Data is collected from –**

A case control study was conducted on ventilated organophosphorus patients admitted to Emergency Medicine of Bapuji Hospital. Patients with history and clinical picture suggestive of acute OP poisoning was studied. Thorough observation of poison container was done and sent for toxicology analysis. Institutional Ethical Committee approval was taken. Written consent was obtained after explaining to patient/relatives in their language.

Patients were divided into two groups of 22 each who fulfill the inclusion – exclusion criteria

- Control group received atropine and oximes only.
- Study group received atropine and oximes along with FFP 2 units (400 ml) on daily basis until patient is extubated.
- Patients were atropinized and atropine infusion given to maintain a state of atropinization with 20% of atropinized dose and titrated accordingly. Injection oximes will be given 30 mg/kg intravenous (IV) bolus followed by 10 mg/kg/h depending up on clinical improvement.
- Gastric lavage and decontamination was done and activated charcoal added.
- Hemodynamic parameters, saturation, muscle power, and CNS status was continuously monitored and recorded regularly. Arterial blood gas (ABG) analysis done once in 24 h and also when required.
- Plasma cholinesterase level was measured on daily basis until extubated
- Ventilation done with synchronized intermittent mandatory ventilation and settings was managed according to ABG status. Antibiotic prophylaxis was given to both groups according to institutional protocol.
- Patients were weaned from ventilator according to clinical assessment of muscle power and respiratory effort.
- Patients were extubated when they achieved extubation criteria and monitored in ICU for respiratory distress for 24 h, and later shifted to stepdown ward.
- Patients were analyzed for increase in serum cholinesterase level, length of ICU stay and mortality rate.

**Methodology:**

After getting informed consent from the patient / bystander, 2 units FFP was transfused on a daily basis to op poisoning patients until extubation. And 2ml blood drawn daily and serial pseudo cholinesterase levels was monitored.

**Statistical analysis:**

- Relevant data was collected, tabulated and analysis was done using SPSS software (latest version).
- Relevant statistical tests was applied.

**RESULTS**

| <b>AGE</b>   |          |             |                       |            |
|--------------|----------|-------------|-----------------------|------------|
| <b>Group</b> | <b>N</b> | <b>Mean</b> | <b>Std. Deviation</b> | <b>t</b>   |
| Control      | 22       | 33.591      | 8.645                 | .843       |
| Cases        | 22       | 36.619      | 14.344                | p=0.404 ns |

| <b>GENDER</b>          |              |                |               |               |
|------------------------|--------------|----------------|---------------|---------------|
|                        |              | <b>Group</b>   |               | <b>Total</b>  |
|                        |              | <b>Control</b> | <b>Cases</b>  |               |
| <b>F</b>               | Count        | 3              | 6             | 9             |
|                        | %            | 13.6%          | 27.3%         | 20.5%         |
| <b>M</b>               | Count        | 19             | 16            | 35            |
|                        | %            | 86.4%          | 72.7%         | 79.5%         |
| <b>Total</b>           | <b>Count</b> | <b>22</b>      | <b>22</b>     | <b>44</b>     |
|                        | <b>%</b>     | <b>100.0%</b>  | <b>100.0%</b> | <b>100.0%</b> |
| a. X2=1.257 p=0.262 ns |              |                |               |               |

| <b>MANNER</b>   |              |                |               |               |
|-----------------|--------------|----------------|---------------|---------------|
|                 |              | <b>Group</b>   |               | <b>Total</b>  |
|                 |              | <b>Control</b> | <b>Cases</b>  |               |
| <b>Suicidal</b> | Count        | 22             | 22            | 44            |
|                 | %            | 100.0%         | 100.0%        | 100.0%        |
| <b>Total</b>    | <b>Count</b> | <b>22</b>      | <b>22</b>     | <b>44</b>     |
|                 | <b>%</b>     | <b>100.0%</b>  | <b>100.0%</b> | <b>100.0%</b> |

| COMPOUNDS  |       |         |        |        |
|--|-------|---------|--------|--------|
|  |       | Group   |        | Total  |
|  |       | Control | Cases  |        |
| Chlorpyrifos   | Count | 8       | 6      | 14     |
|  | %     | 36.4%   | 27.3%  | 31.8%  |
| Dimethoate   | Count | 1       | 0      | 1      |
|  | %     | 4.5%    | 0.0%   | 2.3%   |
| Monocrotophos  | Count | 6       | 2      | 8      |
|  | %     | 27.3%   | 9.1%   | 18.2%  |
| Unknown<br>Op compound (diagosed by<br>toxicological analysis) | Count | 4       | 9      | 13     |
|  | %     | 18.2%   | 40.9%  | 29.5%  |
| Prophenophos   | Count | 2       | 5      | 7      |
|  | %     | 9.1%    | 22.7%  | 15.9%  |
| Quinalphos   | Count | 1       | 0      | 1      |
|  | %     | 4.5%    | 0.0%   | 2.3%   |
| Total  | Count | 22      | 22     | 44     |
|  | %     | 100.0%  | 100.0% | 100.0% |
| a. X2=7.495 p=0.186 ns   |       |         |        |        |

| REASON                           |       |         |       |       |
|----------------------------------|-------|---------|-------|-------|
|                                  |       | Group   |       | Total |
|                                  |       | Control | Cases |       |
| Low GCS                          | Count | 5       | 5     | 10    |
|                                  | %     | 22.7%   | 22.7% | 22.7% |
| Low GCS with respiratory failure | Count | 11      | 6     | 17    |
|                                  | %     | 50.0%   | 27.3% | 38.6% |

|                            |              |               |               |               |
|----------------------------|--------------|---------------|---------------|---------------|
| Type 1 Respiratory failure | Count        | 2             | 8             | 10            |
|                            | %            | 9.1%          | 36.4%         | 22.7%         |
| Type 2 respiratory failure | Count        | 4             | 3             | 7             |
|                            | %            | 18.2%         | 13.6%         | 15.9%         |
| <b>Total</b>               | <b>Count</b> | <b>22</b>     | <b>22</b>     | <b>44</b>     |
|                            | <b>%</b>     | <b>100.0%</b> | <b>100.0%</b> | <b>100.0%</b> |
| a. X2= 5.213 p=0.157 ns-   |              |               |               |               |

| PSEUDOCOLINEESTERASE LEVELS |              |               |               |               |
|-----------------------------|--------------|---------------|---------------|---------------|
|                             |              | Groups        |               | Total         |
|                             |              | Control       | Cases         |               |
| < 200                       |              | 13            | 13            | 26            |
| %                           |              | 59.09%        | 59.09%        | 59.09%        |
| 200-500                     |              | 7             | 5             | 12            |
| %                           |              | 31.81%        | 22.72%        | 27.27%        |
| 500-2000                    |              | 2             | 4             | 6             |
| %                           |              | 9.09%         | 18.18%        | 13.6%         |
| <b>Total</b>                | <b>Count</b> | <b>22</b>     | <b>22</b>     | <b>44</b>     |
|                             | <b>%</b>     | <b>100.0%</b> | <b>100.0%</b> | <b>100.0%</b> |

| STATUS |       |       |         |       |       |
|--------|-------|-------|---------|-------|-------|
|        |       |       | Group   |       | Total |
|        |       |       | Control | Cases |       |
| Status | DAMA  | Count | 7       | 6     | 13    |
|        |       | %     | 31.8%   | 27.3% | 29.5% |
|        | Death | Count | 7       | 2     | 9     |
|        |       | %     |         |       |       |

|                        |          |              |               |               |               |
|------------------------|----------|--------------|---------------|---------------|---------------|
|                        |          | %            | 31.8%         | 9.1%          | 20.5%         |
|                        | Improved | Count        | 8             | 14            | 22            |
|                        |          | %            | 36.4%         | 63.6%         | 50.0%         |
| <b>Total</b>           |          | <b>Count</b> | <b>22</b>     | <b>22</b>     | <b>44</b>     |
|                        |          | <b>%</b>     | <b>100.0%</b> | <b>100.0%</b> | <b>100.0%</b> |
| a. X2=5.752 p=0.042 ns |          |              |               |               |               |

### NO OF. DAYS


| Group   | N  | Mean  | Std. Deviation | t          |
|---------|----|-------|----------------|------------|
| Control | 22 | 5.864 | 2.007          | 3.057      |
| Cases   | 22 | 4.182 | 1.622          | p=0.004 hs |

### PSEUDOCOLINEESTERASE LEVEL PRIOR TO EXTUBATION

|              |              | Cases         |
|--------------|--------------|---------------|
|              | <300         | 11            |
|              | %            | 50.00%        |
|              | 300- 1000    | 3             |
|              | %            | 13.63%        |
|              | >1000        | 8             |
|              | %            | 36.36%        |
| <b>Total</b> | <b>Count</b> | <b>22</b>     |
|              | <b>%</b>     | <b>100.0%</b> |

In our study mean age of case was 36years and control was 33years. Male predominance was observed in both the groups with 72.7% in cases and 86.4% in control. Manner of consumption of all cases were suicidal. The compound consumed in our study was Chlorpyrifos (31.8%), unknown organophosphorus compound (29.5%), Monocrotophos (18.2%) and profenofos (15.9%) of cases. The most common reason for intubation in our study was low GCS with respiratory failure in 38.6% of cases followed by low GCS and type 1 respiratory failure which accounted for 22.7% of cases each. Pseudocholinesterase level at presentation was less than 200 in 59.9 percent of cases, between 200 to 500 in 27.27% of total cases and 500 to 2000 in 13.6% of total cases. 63.6% cases who received FFP showed improvement while 9.1% of cases expired whereas in control 36.4% showed improvement and 31.8% had expired. The mean number of days of hospital stay was 4.1 in cases with SD of 1.62 whereas it was 5.8 in control with SD of 2.00 and this was statistically significant  $p=0.004$ . The pseudocholinesterase level prior to extubation, 50 percent of ffp transfused case have pseudocholinesterase level by 200 to 300, 36.36% have levels between 300 to 1000 and 13.63% have levels above 1000.

#### No of. Days



## DISCUSSION

In our study we had observed that there was significant decrease in mortality (to 9%) in cases who received 2 units of FFP daily compared to control where FFP was not given (i.e 36.4%). Similar findings were observed in study conducted by Dayananda V. et al and Güven M et al where they reported 0% mortality rate in FFP transfused cases.<sup>1,2</sup> Guven M et al further showed that transfusion of FFP prevents intermediate syndrome<sup>2</sup>.

It was also observed that the mean number of days of hospital stay was  $4.1 \pm 1.69$  in cases whereas  $5.8 \pm 2.0$  in control the improvement seen was consistent with the study conducted by Dayanand V et al which also showed significant decrease in ICU stay.<sup>1</sup>

Low pseudocholinesterase level corresponds to severity of poisoning<sup>3</sup>. Majority of our cases presented with severe Organophosphorus poisoning with 59.09% of cases with pseudocholinesterase less than 200. The pseudocholinesterase level prior to extubation in our cases is less than 300 in 50% of cases. The raise of the pseudocholinesterase value in our study with FFP transfusion couldn't be assessed adequately with every 2 units of FFP transfused as the value was less than 200 and not measureable according to our lab reports. Acc to study conducted by StovnerJevery two units of FFP increases serum cholinesterase by  $461.7 \pm 142.1$  IU/L, approximately.<sup>4</sup>



Furthermore due to severe degree of organophosphate poisoning in our study a large amount of it which was proteins bound were probably released and neutralized in daily basis by FFP.

Interestingly in a case by Pazooki S, 4 units FFP were only given on presentation showed no significance in clinical course<sup>5</sup>. The FFP transfused at presentation sequesters only a certain amount of enzyme. In case of severe toxicity large amount of enzyme which is unbound or gradually released from the bound proteins is left free which requires further amount of cholinesterase enzyme present in FFP to be neutralized. This dose of FFP to be determined is inconclusive and further studies need to be done to determine the same.

#### **Conclusion:**

- The use of FFP was found to have mortality benefit and also reduces length of ICU stay.

#### **BIBLIOGRAPHY:**

- 1) Dayananda VP, Bhaskara B, Pateel GN. A study of effectiveness of fresh frozen plasma in organophosphorous compound poisoning in reducing length of Intensive Care Unit stay and in reducing need for tracheostomy. *Anesthesia Essays and Researches*. 2016 May 1;10(2):268-72.
- 2) Güven M, Sungur M, Eser B, Sarı İ, Altuntaş F. The effects of fresh frozen plasma on cholinesterase levels and outcomes in patients with organophosphate poisoning. *Journal of Toxicology: Clinical Toxicology*. 2004 Jan 1;42(5):617-23.
- 3) Hiremath P, Rangappa P, Jacob I, Rao K. Pseudocholinesterase as a predictor of mortality and morbidity in organophosphorus poisoning. *Indian journal of critical care medicine: peer-reviewed, official publication of Indian Society of Critical Care Medicine*. 2016 Oct;20(10):601-4.
- 4) Stovner J, Stadskleiv K. Suxamethoniumapnoea terminated with commercial serumcholinesterase. *Acta Anaesthesiologica Scandinavica*. 1976 Jun;20(3):211-5.
- 5) Pazooki S, Solhi H, Vishteh HR, Shadnia S, Beigi MJ. Effectiveness of fresh frozen plasma as supplementary treatment in organophosphate poisoning. *Med J Malaysia*. 2011 Oct 1;66(4):342-5.